Terui T, et al. - In Japanese patients with palmoplantar pustulosis (PPP), researchers determined the effectiveness and safety of guselkumab, an anti–IL-23 monoclonal antibody. The study sample consisted of 159 patients (mean [SD] age at diagnosis, 46.8 [11.9] years; 126 women [79.2%]). For this investigation, subcutaneous injections of guselkumab, 100 or 200 mg, at weeks 0, 4, and 12, and every 8 weeks thereafter were administered and placebo was given at weeks 0, 4, and 12. The data presented in this work showed a significantly higher proportion of patients in the guselkumab 100-mg group achieved a PPPASI-50 response at week 16 compared to placebo. However, the outcome for the guselkumab 200-mg group was not significant. Findings suggested that targeting interleukin 23 with guselkumab can be an effective and safe treatment alternative for a recalcitrant disease like PPP. There have been no reported severe infections.